{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"7.7"},{"groupId":"OG002","value":"7.1"}]}],"title":"Glomerular filtration rate <30 ml/min/1.73m^2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.5"},{"groupId":"OG001","value":"92.3"},{"groupId":"OG002","value":"92.9"}]}],"title":"Glomerular filtration rate≥ 30 ml/min/1.73m^2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"112"}],"units":"Participants"}],"description":"Renal Impairment was measured by glomerular filtration rate which was calculated using the Modification of Diet in Renal Disease formula. Percentage of participants with renal impairment was reported. Severe renal impairment was defined as a GFR of \\<30ml/min/1.73m2.","groups":[{"description":"Study drug was given by continuous oral daily dosing of two 5 mg tablets.","id":"OG000","title":"Everolimus Randomized (Core Period)"},{"description":"Placebo was given by continuous oral daily dosing of two 5 mg tablets.","id":"OG001","title":"Placebo Randomized (Core Period)"},{"description":"Patients initially randomized in everolimus and patients initially randomized in placebo but who crossed-over to everolimus during extension.","id":"OG002","title":"Everolimus (Core and/or Extension Period)"}],"paramType":"NUMBER","populationDescription":"Safety set consists of all patients who received at least 1 dose of the double-blind study drug with a valid post-baseline assessment. For the everolimus (core/extension) treatment arm, patients received at least 1 dose of everolimus with a valid post-baseline assessment, where baseline was defined as the assessment just before start of everolimus.","reportingStatus":"POSTED","timeFrame":"Day 1 up to 28 days after end of treatment","title":"Percentage of Participants With Renal Impairment","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}